In the last trading session, 2.03 million Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) shares changed hands as the company’s beta touched 0.24. With the company’s per share price at $2.40 changed hands at $0.23 or 10.60% during last session, the market valuation stood at $611.18M. MRVI’s last price was a discount, traded about -379.17% off its 52-week high of $11.50. The share price had its 52-week low at $1.66, which suggests the last value was 30.83% up since then.
Analysts gave the Maravai LifeSciences Holdings Inc (MRVI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.20. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended MRVI as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Maravai LifeSciences Holdings Inc’s EPS for the current quarter is expected to be -0.07.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) trade information
Instantly MRVI was in green as seen at the end of in last trading. With action 16.50%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -55.96%, with the 5-day performance at 16.50% in the green. However, in the 30-day time frame, Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) is 35.59% up.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 52.0% from its current market value. According to analyst projections, MRVI’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -108.33% plunge from its current level, while the stock would need to soar -108.33% for it to hit the projected low.
Maravai LifeSciences Holdings Inc (MRVI) estimates and forecasts
Year-over-year growth is forecast to reach -24.87% down from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 47.46M. 13 analysts are of the opinion that Maravai LifeSciences Holdings Inc’s revenue for the current quarter will be 50M. The company’s revenue for the corresponding quarters a year ago was 73.4M and 65.2M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -35.34%. The estimates for the next quarter sales put growth at -23.31%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -64.27%. The 2025 estimates are for Maravai LifeSciences Holdings Inc earnings to decrease by -180.40%, but the outlook for the next 5-year period is at -17.33% per year.
MRVI Dividends
Maravai LifeSciences Holdings Inc is expected to release its next quarterly earnings report in June.
12 WEST CAPITAL MANAGEMENT LP holds the second largest percentage of outstanding shares, with 9.7254% or 13.21 million shares worth $94.59 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund . With 3.7 shares estimated at $8.87 million under it, the former controlled 2.57% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund held about 2.13% of the shares, roughly 3.07 shares worth around $7.37 million.
